Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODE: CER-001 in Homozygous Familial Hypercholesterolemia
NCT01412034Phase 2Completed
- Sponsor
- ABIONYX Pharma
- Start
- Nov 2011
- Primary completion
- Oct 2013
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of CER-001 in homozygous familial hypercholesterolemia (HoFH), sponsored by ABIONYX Pharma. Primary endpoint: Percent change from baseline to follow-up in carotid mean vessel wall area at 6 months. Started Nov 2011; status: completed.
02
Drugs
CER-001
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NCT01412034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01412034.